

April 2006

Provider Bulletin Number 637b

Professional Providers

Diagnosis Restriction Changes for Amphetamines, Amphetamine Mixtures, and Modafinil

Effective with dates of service on and after May 1, 2006, the following changes will occur for covered diagnoses:

Amphetamines, Amphetamine Mixtures, Amphetamine-like drugs

- Attention Deficit Disorder (ADD) (ICD-9 code 31400) will continue to be a covered diagnosis.
- Attention Deficit Disorder with Hyperactivity (ADHD) (ICD-9 code 31401) will continue to be a covered diagnosis.
- Cataplexy and Narcolepsy (ICD-9 code 347) will continue to be a covered diagnosis.
- Depressive Disorder (ICD-9 code 311) will no longer be a covered diagnosis.

Modafinil (Provigil®)

- Cataplexy and Narcolepsy (ICD-9 code 347) will continue to be a covered diagnosis.
- Obstructive Sleep Apnea/Hypopnea Syndrome (ICD-9 code 78057) will become a covered diagnosis.
- Shift Work Sleep Disorder (ICD-9 code 30745) will become a covered diagnosis.
- Unspecified Hypersomnia (ICD-9 code 78054) will no longer be a covered diagnosis.

Refer to the *Pharmacy Provider Manual* for additional information.

Information about the Kansas Medical Assistance Program as well as provider manuals and other publications are on the KMAP Web site at <https://www.kmap-state-ks.us>.

If you have any questions, please contact the KMAP Customer Service Center at 1-800-933-6593 (in-state providers) or 785-274-5990 between 7:30 a.m. and 5:30 p.m., Monday through Friday.